New & Noteworthy

Submit New & Noteworthy

April 2018

Response to Market Shortages

QuVa Pharma, Inc

As an emerging leader in 503B compounding outsourcing, QuVa Pharma has responded to market demands with increased capability and capacity. Its cGMP ability to produce sterile-to-sterile and API-to-sterile products increases available, safe options for health care providers during times of chronic shortages. QuVa Pharma now has three FDA-registered 503B sterile compounding facilities (two in Texas
and one in New Jersey), and an anticipated 90,000 square-feet of additional space as of Q4 2018.

Click here to view product detail on Findit.

Recent Popular Articles

October 2019 : Cleanrooms & Compounding
October 2019 : Cleanrooms & Compounding
October 2019 : Cleanrooms & Compounding
November 2019

Current Issue

Enter our Sweepstakes now for your chance to win the following prizes:

Just answer the following quick question for your chance to win:

To continue, you must either login or register: